Recalled Diamond Shruumz Linked to Three Deaths, 175 Illnesses, FDA Reports

FDA has identified traces of schedule I controlled substances, prescription drugs and other potentially harmful ingredients in recalled Diamond Shruumz microdosing edibles.

Federal health officials are urging consumers to immediately stop using recalled Diamond Shruumz microdosing edible products, after confirming nearly 200 illnesses nationwide, including three deaths that may be linked to these items.

The Diamond Shruumz microdosing chocolate bars, cones and gummies were originally recalled in July, after it was discovered that the products contained higher than normal amounts of muscimol, a compound found in Amanita mushrooms.

At the time of the initial recall, there were 39 reported illnesses across 20 states, with 23 individuals hospitalized. However, federal officials now report that the contaminated products have been linked to over 175 illnesses in 33 states, resulting in 70 hospitalizations and three fatalities, according to an October 3 Diamond Shruumz recall update from the U.S. Food and Drug Administration (FDA).

Reports of illnesses first surfaced in early June, prompting a joint investigation by the FDA and the Centers for Disease Control and Prevention (CDC). Affected consumers have experienced seizures, loss of consciousness, confusion, irregular heart rates, nausea, vomiting and other serious side effects.

Initially, 12 consumers reported illnesses related to the products, but by July, nearly 40 cases had been confirmed, many requiring hospitalization. By August, the number of affected individuals had surged to over 100, with symptoms including central nervous system depression, agitation and abnormal blood pressure.

Despite the company’s claim that muscimol, a psychoactive compound from mushrooms, was responsible for the illnesses, FDA testing revealed additional substances in the products. These included:

• Acetylpsilocin, a synthetically produced psychedelic drug,
• Psilocin, a schedule I, controlled psychedelic drug,
• Pregabalin, a prescription drug used to treat nerve pain,
• Desmethoxyyangonin, dihydrokavain and kavain–three types of kavalactones found in the kava plant, and
• Isotonic acid, often used in intravenous fluids given in hospitals.

While each ingredient may have known health risks when used, there is little information about the side effects when they are taken together.

Diamond Shruumz products affected by the recall were sold in smoke shops, vape stores and retailers specializing in hemp-derived products like CBD and delta-8 THC. While these products should no longer be available for purchase, federal authorities continue to investigate the cause of the outbreak and will provide updates as new information emerges.

Health officials emphasize that consumers should not purchase or consume Diamond Shruumz products. Any retailers, whether online or in-store, that continue to sell the recalled items should be reported to the FDA immediately to prevent further illnesses or deaths.

If you have consumed these products and are feeling unwell, seek medical attention or contact the Poison Help Line at 800-222-1222.